trending Market Intelligence /marketintelligence/en/news-insights/trending/4SpCgOEiLD5rkjWbSoTrrg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Processa Pharmaceuticals to undertake 1-for-7 reverse stock split

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021

Six trends shaping the industries and sectors we cover in 2021


Processa Pharmaceuticals to undertake 1-for-7 reverse stock split

Processa Pharmaceuticals Inc. will undertake a 1-for-7 reverse stock split of its issued and outstanding common stock, effective Dec. 23.

Processa Pharmaceuticals' shareholders approved the reverse stock split Nov. 7, and the move will help reduce the company's common stock issued and outstanding to approximately 5.5 million from 38.4 million.

The company's shares will continue trading on the OTCQB market under the ticker PCSA.

The Hanover, Md.-based pharmaceutical company is developing medicine for a skin condition known as necrobiosis lipoidica.